Table 1. Features of the 46 patients... | American Society of Hematology

Table 1.

Features of the 46 patients with B-cell lymphoproliferative disorders associated with HCV infection treated with DAAs

	n	%
Male/female	18/28	39/61
MZLs	37	80
Splenic	17	37
Nodal	1	2
Extranodal	15	32
Leukemic	4	9
Others*	5	11
CLL/SLL	4	9
Ann Arbor stage III-IV	35/42	83
B symptoms	6	13
ECOG performance status ≥2	1	2
Hemoglobin <12 g/dL	14/45	31
Platelets <100 × 10⁹/L	10/45	22
Lactate hydrogenase > UNL	10/40	25
β₂-Microglobulin > UNL	20/26	77
Albumin <3.5 g/dL	6/40	15
HCV genotype
1	29	63
2	12	26
3	3	7
4	2	4
Cirrhosis	7	15
Previous chemotherapy	10	22
Previous IFN-based antiviral treatment	12	26
DAAs
Sofosbuvir-based regimen†	39	85
Other regimen‡	7	15

	n	%
Male/female	18/28	39/61
MZLs	37	80
Splenic	17	37
Nodal	1	2
Extranodal	15	32
Leukemic	4	9
Others*	5	11
CLL/SLL	4	9
Ann Arbor stage III-IV	35/42	83
B symptoms	6	13
ECOG performance status ≥2	1	2
Hemoglobin <12 g/dL	14/45	31
Platelets <100 × 10⁹/L	10/45	22
Lactate hydrogenase > UNL	10/40	25
β₂-Microglobulin > UNL	20/26	77
Albumin <3.5 g/dL	6/40	15
HCV genotype
1	29	63
2	12	26
3	3	7
4	2	4
Cirrhosis	7	15
Previous chemotherapy	10	22
Previous IFN-based antiviral treatment	12	26
DAAs
Sofosbuvir-based regimen†	39	85
Other regimen‡	7	15

Median age of patients was 59 years (range, 40-78 years).

ECOG, Eastern Cooperative Oncology Group; UNL, upper normal limit.

Follicular lymphoma (n = 2), lymphoplasmacytic lymphoma (n = 2), and low-grade B-NHL not otherwise specified (n = 1).

Sofosbuvir combined with simeprevir (n = 13), ribavirin (n = 15), daclatasvir (n = 8), or ledipasvir (n = 3).

Paritaprevir/ritonavir/ombitasvir with or without dasabuvir with or without ribavirin (n = 6) or faldaprevir/deleobuvir/ribavirin (n = 1).